OrganiGram reported an adjusted Q (ended Sept 2025) EPS loss of $0.20 versus the Zacks consensus loss of $0.01 (a -1,900% surprise) while revenue rose to $56.91 million, beating estimates by 7.1% and up from $32.77 million a year earlier. The sizeable EPS miss — the company has failed to top consensus EPS in each of the last four quarters — leaves near-term stock direction contingent on management commentary and potential estimate revisions; consensus expects next-quarter EPS of -$0.02 on $51.11 million of revenue and a fiscal-year breakeven on $213.92 million, and Zacks assigns a Hold (Rank #3) with the Medical–Products industry in the bottom 30% of its rankings. Shares have lagged the broader market YTD (+11.8% vs S&P +15.9%), so investors should monitor guidance and analyst revisions for clarity on sustainability amid sector headwinds.
OrganiGram reported an adjusted EPS loss of $0.20 for the quarter ended September 2025 versus the Zacks consensus loss of $0.01, a -1,900% earnings surprise; the company posted a year-ago loss of $0.04. Revenue was $56.91 million, up from $32.77 million year-over-year and 7.1% above consensus, marking the third revenue beat in the last four quarters while EPS has missed consensus in each of those quarters. Shares have risen about 11.8% year-to-date versus the S&P 500’s 15.9% gain and Zacks assigns OGI a Rank #3 (Hold); the Medical - Products industry sits in the bottom 30% of Zacks industries, highlighting sector headwinds. The consensus outlook calls for next-quarter EPS of -$0.02 on $51.11 million and fiscal-year breakeven on $213.92 million, and historical evidence cited in the report links near-term stock moves to earnings-estimate revisions. The disconnect between a solid revenue beat and a large EPS miss points to margin pressure, cost or non-operating items as the driver of the weakness; the company’s earnings-call commentary will be the key catalyst for re-assessing sustainability. Investors should watch analyst estimate revisions, management guidance on margins and cash flow, and peer results (e.g., Tilray’s upcoming release) to gauge whether the revenue growth can convert to consistent profitability.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Overall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
